In vitro effects of the new antifungal compound manogepix (APX001) against the three most clinically relevant species of Sporothrix. [PDF]
Braz J MicrobiolSporotrichosis is an endemic mycosis that pose significant public health challenges, particularly in Brazil, where zoonotic transmission has increased the number of cases in several regions of the country. The disease is caused by Sporothrix genus, with S. brasiliensis, S. schenckii, and S. globosa as the major agents. The currently available therapies
Almeida-Silva F +6 more
europepmc +3 more sources
Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits. [PDF]
Antimicrob Agents Chemother, 2021 Candida endophthalmitis is a serious sight-threatening complication of candidemia that may occur before or during antifungal therapy. Hematogenous Candida meningoencephalitis (HCME) is also a serious manifestation of disseminated candidiasis in premature infants, immunosuppressed children, and ...
Petraitiene R +7 more
europepmc +4 more sources
APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis. [PDF]
Antimicrob Agents Chemother, 2019 APX001, the prodrug of APX001A, is a first-in-class antifungal agent that has a potent activity against Aspergillus fumigatus . The goal of current study was to determine the pharmacodynamic (PD) index and target of APX001 in an immunocompromised murine model of invasive pulmonary aspergillosis against 6
Zhao M +6 more
europepmc +4 more sources
Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis. [PDF]
Antimicrob Agents Chemother, 2018 APX001 is a first-in-class, intravenous and orally available, broad-spectrum antifungal agent in clinical development for the treatment of life-threatening invasive fungal infections. The half-life of APX001A, the active moiety of APX001, is significantly shorter in mice than in humans (1.4 to 2.75 h in mice versus 2 to 2.5 days in humans), making the ...
Zhao Y +8 more
europepmc +3 more sources
Antifungal Resistance in Non‐fumigatus Aspergillus Species
Mycoses, Volume 68, Issue 4, April 2025.ABSTRACT This review provides an in‐depth exploration of antifungal resistance in non‐fumigatus Aspergillus species, mainly focusing on acquired resistance. The available data have been compiled and sometimes re‐analysed. It highlights the increasing prevalence of resistance in non‐fumigatus species belonging to Flavi, Terrei, Nigri, and Nidulantes ...
Elie Djenontin +3 more
wiley +1 more source
The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies
Chemical Biology &Drug Design, Volume 105, Issue 1, January 2025.The future of treating challenging fungal infections lies in novel therapies targeting new antifungal targets, overcoming resistance mechanisms, and exploring innovative dual inhibitors. ABSTRACT Invasive fungal infections (IFIs) pose significant challenges in clinical settings, particularly due to their high morbidity and mortality rates.
Cengiz Zobi, Oztekin Algul
wiley +1 more source
, 2020 Manogepix (APX001A) is the active moiety of the novel drug candidate fosmanogepix (APX001). We previously reported the broad-spectrum activity of manogepix but also observed a correlation between increased manogepix and fluconazole MICs.
Arendrup, Maiken Cavling +1 more
core +1 more source
1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data [PDF]
Open Forum Infectious Diseases, 2018 Sujata M Bhavnani
exaly +1 more source
, 2020 Manogepix (APX001A) is the active moiety of the drug candidate fosmanogepix (APX001), currently in clinical development for the treatment of invasive fungal infections.
Astvad, Karen M.T. +2 more
core +1 more source
, 2018 APX001A is the active moiety of the first-in-class drug candidate APX001. So far, most susceptibility testing studies have examined ≤30 isolates/species, and only one used the EUCAST method. Here, we investigated the in vitro activity of APX001A and five
Astvad, Karen M. T. +3 more
core +1 more source